X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs MERCK LTD - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA MERCK LTD ABBOTT INDIA/
MERCK LTD
 
P/E (TTM) x 39.7 46.4 85.4% View Chart
P/BV x 10.2 7.0 145.5% View Chart
Dividend Yield % 0.7 0.4 167.8%  

Financials

 ABBOTT INDIA   MERCK LTD
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
MERCK LTD
Dec-16
ABBOTT INDIA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs6,1101,060 576.4%   
Low Rs3,996623 641.4%   
Sales per share (Unadj.) Rs1,552.2632.4 245.4%  
Earnings per share (Unadj.) Rs188.845.7 413.0%  
Cash flow per share (Unadj.) Rs196.462.3 315.2%  
Dividends per share (Unadj.) Rs55.0011.00 500.0%  
Dividend yield (eoy) %1.11.3 83.3%  
Book value per share (Unadj.) Rs796.6388.8 204.9%  
Shares outstanding (eoy) m21.2516.60 128.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.31.3 244.7%   
Avg P/E ratio x26.818.4 145.4%  
P/CF ratio (eoy) x25.713.5 190.5%  
Price / Book Value ratio x6.32.2 293.1%  
Dividend payout %29.124.1 121.1%   
Avg Mkt Cap Rs m107,37613,969 768.7%   
No. of employees `0003.31.6 209.9%   
Total wages/salary Rs m3,9371,487 264.8%   
Avg. sales/employee Rs Th9,929.36,631.9 149.7%   
Avg. wages/employee Rs Th1,185.1939.2 126.2%   
Avg. net profit/employee Rs Th1,207.7479.4 251.9%   
INCOME DATA
Net Sales Rs m32,98510,498 314.2%  
Other income Rs m1,170242 482.6%   
Total revenues Rs m34,15510,741 318.0%   
Gross profit Rs m5,2451,135 462.0%  
Depreciation Rs m162276 58.8%   
Interest Rs m380-   
Profit before tax Rs m6,2151,102 563.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,203343 641.6%   
Profit after tax Rs m4,012759 528.7%  
Gross profit margin %15.910.8 147.0%  
Effective tax rate %35.431.1 113.8%   
Net profit margin %12.27.2 168.3%  
BALANCE SHEET DATA
Current assets Rs m22,6556,410 353.5%   
Current liabilities Rs m6,6818,828 75.7%   
Net working cap to sales %48.4-23.0 -210.2%  
Current ratio x3.40.7 467.1%  
Inventory Days Days6558 112.3%  
Debtors Days Days2938 75.9%  
Net fixed assets Rs m8351,406 59.4%   
Share capital Rs m213166 128.0%   
"Free" reserves Rs m16,7156,286 265.9%   
Net worth Rs m16,9286,455 262.3%   
Long term debt Rs m00-   
Total assets Rs m24,1628,828 273.7%  
Interest coverage x163.7NM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.41.2 114.8%   
Return on assets %16.88.6 195.0%  
Return on equity %23.711.8 201.6%  
Return on capital %36.917.1 216.3%  
Exports to sales %08.3 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs mNA2,209 0.0%   
Fx inflow Rs m369959 38.4%   
Fx outflow Rs m3,8072,612 145.7%   
Net fx Rs m-3,438-1,653 208.0%   
CASH FLOW
From Operations Rs m1,5271,070 142.7%  
From Investments Rs m-2,148-750 286.6%  
From Financial Activity Rs m-1,024-150 683.8%  
Net Cashflow Rs m-1,646171 -962.9%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 51.8 144.8%  
Indian inst/Mut Fund % 7.9 18.2 43.4%  
FIIs % 0.1 1.0 10.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 29.1 58.8%  
Shareholders   18,270 28,591 63.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   FDC LTD.  UNICHEM LAB  WYETH LTD  AJANTA PHARMA  FULFORD INDIA  

Compare ABBOTT INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Positively, Aavas Financiers IPO, and Top Stocks in Action Today(Pre-Open)

Share markets in India ended on a positive note yesterday with gains largely seen in the banking sector and healthcare sector.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Sep 25, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - J.B.CHEMICALS COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS